These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 15901483

  • 1. Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease.
    Dalbem A, Silveira CV, Pedroso MF, Breda RV, Werne Baes CV, Bartmann AP, da Costa JC.
    Brain Res; 2005 Jun 21; 1047(2):148-58. PubMed ID: 15901483
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
    Pandey M, Borah A, Varghese M, Barman PK, Mohanakumar KP, Usha R.
    Neurochem Int; 2009 Nov 21; 55(6):431-7. PubMed ID: 19410615
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
    Tadros MG, Khalifa AE, Abdel-Naim AB, Arafa HM.
    Pharmacol Biochem Behav; 2005 Nov 21; 82(3):574-82. PubMed ID: 16337998
    [Abstract] [Full Text] [Related]

  • 8. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.
    Cirillo G, Maggio N, Bianco MR, Vollono C, Sellitti S, Papa M.
    Neurochem Int; 2010 Jan 21; 56(1):152-60. PubMed ID: 19799953
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML, Valanzano A, Pezzola A, March ZD, Fusco FR, Popoli P, Calamandrei G.
    Behav Brain Res; 2007 Jan 25; 176(2):216-21. PubMed ID: 17123640
    [Abstract] [Full Text] [Related]

  • 12. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J.
    Synapse; 2002 Apr 25; 44(1):23-35. PubMed ID: 11842443
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
    Kumar P, Kumar A.
    Behav Brain Res; 2010 Jan 05; 206(1):38-46. PubMed ID: 19716383
    [Abstract] [Full Text] [Related]

  • 16. Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome.
    Di Filippo M, Tozzi A, Ghiglieri V, Picconi B, Costa C, Cipriani S, Tantucci M, Belcastro V, Calabresi P.
    Biol Psychiatry; 2010 Apr 01; 67(7):666-71. PubMed ID: 19818432
    [Abstract] [Full Text] [Related]

  • 17. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
    Kumar P, Kumar A.
    Eur J Pharmacol; 2009 Aug 01; 615(1-3):91-101. PubMed ID: 19445928
    [Abstract] [Full Text] [Related]

  • 18. [Behavior characterization of a model of Huntington's disease in rats, induced by quinolinic acid].
    Francis L, Cruz R, Antúnez I, Rosillo JC.
    Rev Neurol; 2009 Aug 01; 30(11):1016-21. PubMed ID: 10904945
    [Abstract] [Full Text] [Related]

  • 19. Asymmetric spike-timing dependent plasticity of striatal nitric oxide-synthase interneurons.
    Fino E, Paille V, Deniau JM, Venance L.
    Neuroscience; 2009 Jun 02; 160(4):744-54. PubMed ID: 19303912
    [Abstract] [Full Text] [Related]

  • 20. Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease.
    Duran-Vilaregut J, del Valle J, Manich G, Camins A, Pallàs M, Vilaplana J, Pelegrí C.
    Neuropathol Appl Neurobiol; 2011 Aug 02; 37(5):525-37. PubMed ID: 21175737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.